A WIRB-Copernicus Group Company

New England IRB Advantage

New England IRB is the premier central IRB, providing quality study review services, merging quick turnaround with ethical support of study participants. No other AAHRPP-accredited IRB provides all of these services to our clients:


  • Full AAHRPP accreditation status (third renewal awarded March 2010)
  • In good standing with FDA (most recent audit: August 2011 — no findings)
  • Multi-tiered QA process, including full-time QA specialist to review all documents
  • Reviews all therapeutic areas and phases (including hybrid phase I/II), of drug, biologic (including vaccine), device, post-approval, socio-behavioral, and patient reported outcomes studies.

Review Timelines

  • One-week protocol review turnaround, including notification of Board results
  • Two weekly protocol submission deadlines (Wednesdays, Fridays at noon)
  • 24-hr site review, including notification

MyConnexus Web Portal

  • Sponsors, CROs and sites submit documents directly for Board review
  • 24/7 secure access to active and archived study documents
  • Reporting capabilities to track and monitor study and site approvals
  • Configurable based on study and communication preferences

Customer Service and Flexibility

  • Single point of contact on dedicated client study team
  • Informal Board Chair review of draft protocol and ICF (at no additional fee)
  • Pre-submission kick-off meeting to discuss logistics, timing and communication (no additional fee)